Steward Partners Investment Advisory LLC lifted its position in AstraZeneca plc (NYSE:AZN) by 11.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 19,570 shares of the company’s stock after buying an additional 1,959 shares during the period. Steward Partners Investment Advisory LLC’s holdings in AstraZeneca were worth $774,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in AstraZeneca by 35.2% during the 2nd quarter. FMR LLC now owns 20,243,181 shares of the company’s stock worth $710,738,000 after purchasing an additional 5,272,590 shares in the last quarter. Jennison Associates LLC bought a new position in AstraZeneca during the 2nd quarter worth about $676,716,000. Fisher Asset Management LLC increased its holdings in AstraZeneca by 4.3% during the 2nd quarter. Fisher Asset Management LLC now owns 13,079,941 shares of the company’s stock worth $459,237,000 after purchasing an additional 535,782 shares in the last quarter. Northern Trust Corp increased its holdings in AstraZeneca by 45.2% during the 2nd quarter. Northern Trust Corp now owns 3,467,814 shares of the company’s stock worth $121,755,000 after purchasing an additional 1,079,790 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in AstraZeneca by 106.6% during the 3rd quarter. Bank of Montreal Can now owns 1,881,954 shares of the company’s stock worth $74,469,000 after purchasing an additional 970,857 shares in the last quarter. Institutional investors and hedge funds own 16.06% of the company’s stock.
In other AstraZeneca news, major shareholder Plc Astrazeneca acquired 600,000 shares of AstraZeneca stock in a transaction dated Monday, October 22nd. The stock was bought at an average cost of $5.00 per share, for a total transaction of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
A number of equities analysts have issued reports on the company. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, July 16th. Guggenheim assumed coverage on AstraZeneca in a report on Monday, October 8th. They set a “buy” rating for the company. Wolfe Research assumed coverage on AstraZeneca in a report on Tuesday, October 23rd. They set an “outperform” rating for the company. Finally, Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $40.34.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Yield Curve
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.